Selected publications
- A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2016 Academic Article GET IT
-
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 27 -
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Breast cancer research : BCR.
2013
Academic Article
GET IT
Times cited: 32 - High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leukemia & lymphoma. 2012 Academic Article GET IT
- Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2012 Academic Article GET IT
- Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 2011 Academic Article GET IT
-
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Expert review of anticancer therapy.
2011
Information Resource
GET IT
Times cited: 131 -
Adjuvant taxanes: more to the story.
Clinical breast cancer.
2010
Information Resource
GET IT
Times cited: 9 -
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs.
2008
Academic Article
GET IT
Times cited: 24 -
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Molecular cancer therapeutics.
2002
Academic Article
GET IT
Times cited: 30